Association Between Vitamin D and the Development of Uterine Fibroids
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Xueqiong Zhu, PHD
- Phone Number: 13906640759
- Email: zjwzzxq@163.com
Study Locations
-
-
Zhejiang
-
Wenzhou, Zhejiang, China, 325000
- The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1. Patients are willing to cooperate with the follow-up and sign informed consent;
- 2. Females aged 35-50 who are diagnosed as having uterine fibroids by transvaginal or abdominal ultrasonography;
- 3. The maximum average diameter of intramural myoma is ≤ 4cm,≥ 1cm; The amount of myoma is less than 4;
- 4. Serum 25-hydroxyvitamin D3 < 30 ng/ml, ≥ 12 ng/ml.
Exclusion Criteria:
- 1. Patients with heavy menstrual bleeding (>80.0 mL), menstrual disorders, pelvic discomfort, infertility, or other indications for operation;
- 2. Patients complicated with myoma degeneration and adenomyosis that were suspected or diagnosed by ultrasound or gynecologic examination;
- 3. Allergic to vitamin D3;
- 4. Use of sexual hormone, mifepristone, gonadotropin-releasing hormone agonist (GnRHa), or other medication which is likely to interfere with uterine fibroids within 3 months;
- 5. Pregnancy, lactation, postmenopause, or planned pregnancy within two years;
- 6. Suspected or identified as other tumors of genital tract;
- 7. History of osteoporosis or vitamin D deficiency taking vitamin D supplements within previous one month;
- 8. History of autoimmune diseases, infectious diseases (tuberculosis, AIDS), autoimmune diseases, digestive system diseases (malabsorption, crohn disease, and dysentery);
- 9. Alanine aminotransferase (ALT) or aspartate transaminase(AST) more than 3 times of the normal upper limit, total bilirubin (TBIL) more than 2 times of the normal upper limit;
- 10. Creatinine levels≥1.4 mg/dL (123μmol/L) or creatinine clearance ≤ 50 mL/min;
- 11. History of malignant tumors;
- 12. Simultaneous participation in another clinical study with investigational medicinal product(s) or researcher thinks the subjects are not suitable for this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: vitamin D deficiency treatment group
patients with vitamin D deficiency (12 ng/ml ≤ serum 25-hydroxyvitamin D3 < 20 ng/ml)and uterine fibroids receive 1600 IU/day of vitamin D3 oral capsule for two years
|
Non-Vitamin D3 Drops group Patients in this group would take nothing.
|
|
No Intervention: vitamin D deficiency control group
patients with vitamin D deficiency (12 ng/ml ≤ serum 25-hydroxyvitamin D3 < 20 ng/ml)and uterine fibroids receive regular follow-up.
|
|
|
Experimental: vitamin D insufficiency treatment group
patients with vitamin D insufficiency (20 ng/ml ≤ serum 25-hydroxyvitamin D3 < 30 ng/ml) and uterine fibroids receive 800 IU/d of vitamin D3
|
Non-Vitamin D3 Drops group Patients in this group would take nothing.
|
|
No Intervention: vitamin D insufficiency control group
patients with vitamin D insufficiency (20 ng/ml ≤ serum 25-hydroxyvitamin D3 < 30 ng/ml)and uterine fibroids receive regular follow-up.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
volume of the total fibroids
Time Frame: two years after treatment
|
percent change in volume of the largest fibroid compared to baseline in different groups
|
two years after treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
percentage of subjects undergoing other medical or surgical treatment of uterine fibroids
Time Frame: two years after treatment
|
percentage of subjects undergoing other medical or surgical treatment of uterine fibroids
|
two years after treatment
|
|
Hypercalcemia
Time Frame: Two years after treatment
|
The level of serum calcium > 2.5 mmol/L
|
Two years after treatment
|
|
abnormal liver function
Time Frame: Two years after treatment
|
Alanine aminotransferase (ALT) or aspartate transaminase (AST) more than 3 times of the normal upper limit, total bilirubin (TBIL) more than 2 times of the normal upper limit
|
Two years after treatment
|
|
urinary calculus
Time Frame: Two years after treatment
|
urinary calculus
|
Two years after treatment
|
|
abnormal renal function
Time Frame: Two years after treatment
|
Creatinine levels ≧ 1.4 mg/dL (123μmol/L) or creatinine clearance ≦ 50 mL/min
|
Two years after treatment
|
|
volume of the largest fibroid
Time Frame: One year after treatment
|
percent change in volume of the largest fibroid compared to baseline in different groups
|
One year after treatment
|
|
volume of the total fibroids
Time Frame: One year after treatment
|
percent change in volume of the total fibroids compared to baseline in different groups
|
One year after treatment
|
|
volume of the largest fibroid
Time Frame: two years after treatment
|
percent change in volume of the largest fibroid compared to baseline in different groups
|
two years after treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Nutrition Disorders
- Connective Tissue Diseases
- Avitaminosis
- Deficiency Diseases
- Malnutrition
- Neoplasms, Connective Tissue
- Neoplasms, Muscle Tissue
- Vitamin D Deficiency
- Leiomyoma
- Myofibroma
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vitamin D
- Cholecalciferol
Other Study ID Numbers
Other Study ID Numbers
- SAHoWMU-CR2017-07-126
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.